(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

COMPOSTO CRISTALINO DE UM ANTAGONISTA DE LPAR1

Em AnáliseInvention PatentPCT · US2024013232

Application data

Invention Patent COMPOSTO CRISTALINO DE UM ANTAGONISTA DE LPAR1 de CONTINEUM THERAPEUTICS, INC. — IPC A61K 31/33
Invention Patent COMPOSTO CRISTALINO DE UM ANTAGONISTA DE LPAR1 de CONTINEUM THERAPEUTICS, INC. — IPC A61K 31/33. Drawing published by the INPI in the Industrial Property Gazette.

Number

112025015243

Type

Invention Patent

Filing

01/26/2024

Publication

05/05/2026

PCT

US2024013232

Progress at the INPI

Examination not yet requested
  1. Filing01/26/24
  2. Publication
  3. Examination
  4. Allowance
  5. Grant
  6. In force

Examination has not been requested yet. Without that request by 01/26/2027, the application is definitively abandoned (art. 33 of the Brazilian IP Act).

Deadline to request examination:01/26/2027(154 days left)

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 05/05/2026. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

CONTINEUM THERAPEUTICS, INC.

US

Inventors

A. C. (pessoa física)

US

J. R. (pessoa física)

US

L. V. (pessoa física)

US

T. S. (pessoa física)

US

Y. X. (pessoa física)

US

Technical data

Priority claims

US

63/481,956 · 01/27/2023

Abstract

COMPOSTO CRISTALINO DE UM ANTAGONISTA DE LPAR1. São aqui descritos, entre outros, um composto cristalino de um antagonista de LPAR1, composições farmacêuticas incluindo o composto cristalino e métodos de tratamento usando os mesmos.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Notificação de entrada na fase nacional - PCT

#1.3

05/05/2026

RPI 2887

Alteração de dados cadastrais

#1.1

08/05/2025

RPI 2848

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.